Clinical trials: Head and Neck
Head and Neck Neoplasms, Carcinoma, Squamous Cell
LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
This randomised, open-label, phase III study will be performed in patients with R/M head and neck squamous cell carcinoma (HNSCC) who have progressed after platinum-based therapy.
- Trial name
- NCT01345682
- Testing
- Afatinib, Methotrexate
- Where
- 101 sites in United States, Argentina and 17 more
- Volunteers
- 483 people
- Sponsor
- Boehringer Ingelheim
Head and Neck Squamous Cell Carcinoma
A Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract
The purpose of this trial is to determine whether or not Cialis (tadalafil) administered to head and neck squamous cell cancer patients augments immune response.
- Trial name
- NCT00894413
- Testing
- Tadalafil
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cancer, Carcinoma
PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
To estimate the effect of second-line panitumumab monotherapy on objective response in patients with metastatic or recurrent squamous cell carcinoma of head and neck (SCCHN).
- Conditions
- Cancer, Carcinoma, Head and Neck Cancer, Metastases
- Trial name
- NCT00446446
- Testing
- Panitumumab
- Volunteers
- 52 people
- Sponsor
- Amgen
Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
This randomized phase II trial studies how well paclitaxel with or without cixutumumab works in treating patients with esophageal cancer or gastroesophageal junction cancer that has spread to other places in the body…
- Conditions
- Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Adenocarcinoma
- Trial name
- NCT01142388
- Testing
- Cixutumumab, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 232 sites in United States
- Volunteers
- 94 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma
Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma
The primary hypothesis of this study is that the addition of mammalian target of rapamycin (mTOR) blockade to conventional epidermal growth factor receptor (EGFR) blockade will result in synergistic clinical activity in Squamous…
- Trial name
- NCT01009203
- Testing
- Erlotinib, Temsirolimus
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- New Mexico Cancer Research Alliance
Carcinoma of the Head and Neck
Combination of Taxotere and Oxaliplatin in Squamous Cell Carcinoma of the Head and Neck
This research study is for subjects with squamous cell cancer of the head and neck which is not solely treatable with surgery or radiation.
- Trial name
- NCT00184028
- Testing
- Taxotere, Oxaliplatin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Southern California
Head and Neck Cancer
Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN
This research study is studying immunotherapy in combination with radiation therapy as a possible treatment for head \& neck cancer that has worsened or spread to another organ or part of your body.
- Trial name
- NCT03085719
- Testing
- Pembrolizumab, Radiation
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Dana-Farber Cancer Institute
Neoplasms
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
The purpose of this study is to evaluate if the combination of GSK3359609 and tremelimumab is safe and tolerable (Part 1) and provides significant survival benefit to subjects with relapsed/refractory (R/R) Head and Neck Squamous…
- Trial name
- NCT03693612
- Testing
- feladilimab, Tremelimumab, Docetaxel
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- GlaxoSmithKline
Head and Neck Cancer, Oropharyngeal Cancer
Robotic Assisted Surgery in Upper Aerodigestive Tract Surgery
To evaluate the use of the daVinci Robotic System for better visibility and access of head and neck lesions and decreased amount of surgery time.
- Conditions
- Head and Neck Cancer, Oropharyngeal Cancer, Hypopharyngeal Cancer, Upper Aerodigestive Tract Neoplasms
- Trial name
- NCT00473564
- Testing
- da Vinci® Robotic System
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- University of Alabama at Birmingham
Osteoradionecrosis
Management of Mandibular ORN: PENTO as Medical Treatment
Mandibular osteoradionecrosis, despite its low incidence, remains being the most problematic and irreversible complication after head and neck radiotherapy with no medical treatment to limit or reduce symptoms.
- Trial name
- PENTO (NCT02368457)
- Testing
- Pentoxifylline and Tocopherol
- Where
- Spain
- Volunteers
- 24 people
- Sponsor
- Hospital Vall d'Hebron
Head and Neck Cancer
Central Pain Syndrome in Survivors of Head and Neck Cancer
This is a cross-sectional pilot study of head and neck cancer survivors who have completed multi-modal treatment to assess and characterize the presence of distinct pain syndromes.
- Trial name
- NCT04128267
- Testing
- IPC-1000, Magnetic resonance imaging, Correlative Studies
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Vanderbilt-Ingram Cancer Center
Urinary Bladder Cancer, Melanoma
MAGE-A4ᶜ¹º³²T for Multi-Tumor
This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung…
- Conditions
- Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer
- Trial name
- NCT03132922
- Testing
- Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
- Where
- 11 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- USWM CT, LLC
Carcinoma, Squamous Cell, Oral Cancer
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
Participants in this study have a type of cancer called squamous cell carcinoma of the head and neck (SCCHN). Their SCCHN has spread around the area where the cancer first started. This is called locally-advanced SCCHN.
- Conditions
- Carcinoma, Squamous Cell, Oral Cancer, Oropharynx Cancer, Larynx Cancer
- Trial name
- NCT03174275
- Testing
- Durvalumab, Carboplatin, Nab-paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Esophageal Neoplasms, Stomach Neoplasms
Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma
The purpose of this study is to evaluate the progression free survival of capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin) in previously untreated metastatic esophagogastric adenocarcinomas.
- Conditions
- Esophageal Neoplasms, Stomach Neoplasms, Neoplasm Metastasis
- Trial name
- XAGastric (NCT00447330)
- Testing
- capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Duke University
ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Radiofrequency Ablation for Patients With Esophageal Squamous Cell Neoplasia
Patients with MGIN, HGIN or flat-type early SCCA of the esophagus will be treated on 3 month intervals with Radiofrequency Ablation (RFA) until complete eradication (CR: no MGIN or worse in the biopsies) will be achieved.
- Trial name
- NCT02047305
- Testing
- Radiofrequency Ablation
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Covidien, GI Solutions
Solid Tumors, ER/PR Positive Breast Cancer
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
This is a Phase I study to understand the biodistribution of MM-398 and to determine the feasibility of using Ferumoxytol as a tumor imaging agent.
- Conditions
- Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis
- Trial name
- NCT01770353
- Testing
- Ferumoxytol, MM-398
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- Ipsen
Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).
- Conditions
- Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma
- Trial name
- NCT04068896
- Testing
- NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane
- Where
- 20 sites in United States
- Volunteers
- 89 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Esophageal Cancer, Gastric Cancer
Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer
The purpose of this study is to find out what effects, good and/or bad, pembrolizumab in combination with trastuzumab and chemotherapy, has on the patients' esophagogastric cancer.
- Trial name
- NCT02954536
- Testing
- pembrolizumab, trastuzumab, capecitabine
- Where
- 8 sites in United States
- Volunteers
- 37 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Mucositis, Oral Complications
Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
This randomized pilot clinical trial studies whether acetylcysteine oral rinse will lessen saliva thickness and painful mouth sores in patients with head and neck cancer undergoing radiation therapy.
- Conditions
- Mucositis, Oral Complications, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip
- Trial name
- NCT02123511
- Testing
- acetylcysteine, quality-of-life assessment, questionnaire administration
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Mayo Clinic
Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer
The purpose of this clinical study is to establish the safety profile, determine the maximum tolerated dose (MTD) and recommend a Phase 2 dose and schedule of SRA737; and to evaluate the efficacy of SRA737 in…
- Trial name
- NCT02797964
- Testing
- SRA737
- Where
- 15 sites in United Kingdom
- Volunteers
- 107 people
- Sponsor
- Sierra Oncology LLC - a GSK company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.